BioDlink International Company Limited (01875.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

812.8x

Market Cap

HKD 2.75B

MomentumView details →

1D Return

−0.39%

YTD Return

+51.80%

RSI (14)

50.5

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

812.8x

Market Cap

HKD 2.75B

RSI (14)

50.5

MomentumView details →

1D Return

−0.39%

YTD Return

+51.80%

ProfitabilityView details →

Gross Margin

53.98%

Net Margin

−9.88%

EBITDA Margin

0.19%

ROE (TTM)

−25.20%

ROA (TTM)

−13.20%

Asset Turnover

1.29x

GrowthView details →

Revenue YoY

+0.42%

EPS YoY

—

FCF YoY

+102.33%

Revenue CAGR 3Y

+19.13%

EPS CAGR 3Y

—

EBITDA YoY

−95.37%

EarningsView details →

EPS (Actual)

−HKD 0.09

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.57x

Current Ratio

2.15x

Quick Ratio

1.67x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

1.57B

Net Income (TTM)

−154.88M

Op. CF (TTM)

104.74M

Latest newsMore news →

TOT Biopharm reported an interim net loss of RMB 58.52 million for the six months ended June 30, 2026, compared with a net profit of RMB 4.06 million a year earlier, with revenue down 49.7% year-on-year to RMB 246 million.13d ago

Similar companies

Soleno Therapeutics, Inc.SLNO Nurix Therapeutics, Inc.NRIX SELLAS Life Sciences Group, Inc.SLS Viva Biotech Holdings01873.HK Beijing Luzhu Biotechnology Co., Ltd.02480.HK Genor Biopharma Holdings Limited06998.HK Find similar companies →

Latest newsMore news →

TOT Biopharm reported an interim net loss of RMB 58.52 million for the six months ended June 30, 2026, compared with a net profit of RMB 4.06 million a year earlier, with revenue down 49.7% year-on-year to RMB 246 million.13d ago